Emmaus Life Sciences, Inc. - Company Summary

Business Focus

Type: Commercial-stage biopharmaceutical company
Primary Activity: Discovery, development, marketing, and sale of treatments and therapies, mainly targeting rare and orphan diseases.

Endari® (prescription-grade L-glutamine oral powder)
- Indication: Approved by the FDA to reduce acute complications of sickle cell disease (SCD) in patients aged 5 years and older.
- Additional Approvals:
  - April 2022: UAE (UAE Ministry of Health and Prevention)
  - Nov-Dec 2022: Qatar and Kuwait
  - May 2023: Bahrain
  - July 2023: Oman
- Pending Approval: Application in Saudi Arabia; allowed on a named-patient basis referencing FDA approval.

U.S. Sales:
- Sold through non-exclusive distributors.
- Until August 2024: Marketed and sold by an internal commercial sales team.
- October 2024: Termination of the Chief Commercialization Officer employment.
- Distributors include: AmerisourceBergen, McKesson, Cardinal Health, CVS Caremark.
- Key distributors each accounted for more than 20% of net revenue in 2024; combined roughly 45%.
International Sales:
- Exclusive distribution agreements in the Gulf Cooperation Council (GCC) and Middle East / North Africa (MENA).
- Market authorizations obtained in UAE, Qatar, Kuwait, Bahrain, Oman.
- Ongoing applications in other jurisdictions.
- Recently recognized market exclusivity in Saudi Arabia in January 2025.

Employees:
- 35 employees (as of December 31, 2024).
- 34 are full-time.
Revenue:
- 2024: $16.7 million (net from product sales).
- 2023: $29.6 million.
Net Loss:
- 2024: $6.5 million.
- 2023: $3.7 million.
Accumulated Deficit: Approximately $262.6 million as of December 31, 2024.
Cash & Equivalents: $1.4 million as of December 31, 2024.
Business Outlook: Continuous losses expected; future operations depend on raising additional capital through loans, equity, licensing, or strategic deals.

Endari® Efficacy:
- FDA approval based on a 48-week Phase 3 trial with 230 patients aged 5-58 with SCD.
- Demonstrated reductions in sickle cell crisis frequency, hospitalizations, days hospitalized, and incidents of acute chest syndrome.
- Clinical Results Highlights (Endari vs placebo):
  - Median crises: 3 vs 4.
  - Hospitalizations: 2 vs 3.
  - Cumulative hospital days: 6.5 vs 11.
  - Time to first crisis: 84 days vs 54 days.
  - Acute chest syndrome: 8.6% vs 23.1%.
Safety Profile: Well tolerated with common adverse reactions including constipation, nausea, headache, abdominal pain, cough, extremity pain, back pain, and chest pain.

SCD (sickle cell disease):
- Affects approximately 20-25 million worldwide.
- U.S. prevalence: Estimated 100,000 patients.
- Majorly affects individuals of African descent.
- Complications include pain crises, organ damage, stroke, and infection.
- Current treatments include hydroxyurea (approved in 2017), and newer therapies like crizanlizumab and voxelotor (withdrawn in 2024), and gene therapies.
- Existing standard therapy involves opioid pain management, which poses addiction risks.
- Market Challenges: Expires orphan drug exclusivity (July 2024); generic competition like ANI’s L-Glutamine Oral Powder affects market share and reimbursement.
- International Focus: Expanding to Middle East and North African regions, with regulatory approvals in several countries.

Dependence on a limited number of distributors and a single manufacturing source for PGLG (Ajinomoto or a packager).
Regulatory compliance costs and risks.
Competition from large pharmaceutical companies and generic manufacturers.
Ongoing losses and need for additional funding.
Risks include market acceptance, reimbursement issues, manufacturing, and regulatory delays.

Products: Only one commercial product (Endari®), for sickle cell disease.
Employees: 35 full-time.
Revenue (2024): $16.7 million.
Net Loss (2024): $6.5 million.
Market: Global expansion with approvals mainly in MENA; US market affected by generic competition.
Financial Health: Significant accumulated losses, limited cash ($1.4 million), future dependence on raising capital and strategic partnerships.